Am I a Candidate for Embryo Genetic Testing PGT?

People may be candidates for genetic testing of embryos, known as preimplantation genetic testing (PGT), when they are having IVF and have a known genetic risk, a history suggesting chromosome-related embryo problems, or a specific clinical reason identified during fertility assessment. PGT is optional and not suitable or necessary for every IVF patient, so decisions should be made with a fertility specialist and, when appropriate, a genetic counselor.

Overview: Who May Be a Candidate for PGT?

Am I a candidate for genetic testing embryos PGT? A person or couple may be a candidate if they are planning IVF and have a known inherited genetic condition, a chromosome rearrangement, or a reproductive history that raises concern about embryo chromosome differences. PGT is not routinely needed for every person having IVF; eligibility depends on medical history, genetic findings, age, fertility factors, and personal goals.

Preimplantation genetic testing is a group of laboratory tests performed on a small sample of cells taken from an embryo before transfer. It is used alongside IVF because embryos must be created and developed in the laboratory before testing can take place. The purpose is to provide information that may help the care team and patient decide which embryo, if any, to consider for transfer.

PGT has different forms. PGT-M is used when there is a known risk of a single-gene condition in a family. PGT-SR is designed for people with certain structural chromosome rearrangements. PGT-A assesses whether an embryo sample appears to have the expected number of chromosomes; its use should be individualized rather than assumed to benefit everyone. For a fuller explanation of the test and IVF pathway, see genetic testing of embryos (PGT).

How PGT Works and What It Can Test For

Embryos contain genetic material from both egg and sperm. After IVF, embryos are usually cultured for several days until they reach the blastocyst stage. A trained embryology team removes a few cells from the outer layer, which is the part that generally contributes to the placenta. The embryo is then frozen while the sample is analyzed in a specialized genetics laboratory.

PGT-M may be considered when one or both intended parents carry, or are known to be affected by, a specific single-gene condition. Before an IVF cycle, the laboratory often needs to develop and validate a tailored test for the family. This preparation can take time and may require genetic reports or samples from relatives, depending on the condition.

PGT-SR may be relevant when one partner has a balanced translocation, inversion, or another structural chromosome change. Although the carrier may be healthy, some embryos may inherit an unbalanced chromosome arrangement. PGT-A is different: it evaluates chromosome copy number in an embryo biopsy sample, but it does not diagnose all genetic diseases, birth differences, or developmental concerns.

Results are used to classify embryos according to the testing approach and the laboratory’s reporting system. Not every embryo will be suitable for testing or available for transfer. A genetics professional can explain what a result can and cannot tell an individual family.

Eligibility Criteria: When PGT May Be Considered

PGT is most clearly considered when there is a defined genetic indication. This may include a previous child or pregnancy affected by a known inherited condition, a confirmed carrier result in one or both partners, or a family history in which a specific disease-causing genetic variant has been identified. A genetic counselor can help clarify inheritance patterns and discuss whether PGT-M is possible.

It may also be discussed for people with a known structural chromosome rearrangement, such as a balanced translocation. In these situations, PGT-SR may help identify embryos that do not show the unbalanced chromosome pattern targeted by the test. Previous repeated miscarriages or infertility sometimes lead to chromosome evaluation, although testing is not appropriate for every person with these experiences.

Some IVF patients ask about PGT-A because embryo chromosome differences become more common with increasing egg age. It may be considered in selected circumstances, including certain prior IVF outcomes, but evidence does not support treating it as a universal step for all patients. The likely usefulness depends on the number of embryos expected, ovarian reserve, age, prior treatment history, and the couple’s priorities.

• Known carrier status or a diagnosed single-gene condition in a prospective parent
• A prior pregnancy, child, or close family member affected by a known genetic condition
• A confirmed chromosome rearrangement in one prospective parent
• Selected histories of miscarriage, unsuccessful IVF, or embryo chromosome concerns after individualized evaluation
• A need for IVF for fertility reasons, with a separate genetic indication for testing

PGT is generally not a substitute for carrier screening, diagnostic genetic testing, or prenatal care. It is also not designed for non-medical trait selection. Regulations, laboratory capabilities, and ethical guidance may affect which tests are available.

Pre-Assessment and the Step-by-Step Procedure

The first step is a fertility consultation and genetic review. The clinician may assess menstrual and reproductive history, semen parameters, ovarian reserve, ultrasound findings, previous IVF records, and relevant medical conditions. Genetic reports should be brought to the appointment where possible. A pre-assessment form can help the team gather this information before the consultation and identify whether genetics counseling or additional testing is needed.

If PGT is suitable, the team plans an IVF cycle. Ovarian stimulation medicines encourage several eggs to mature, and monitoring appointments use ultrasound and blood tests to guide timing. Eggs are collected in a short procedure, usually with sedation or anesthesia. They are fertilized in the laboratory, often by intracytoplasmic sperm injection (ICSI) when PGT is planned, to reduce the chance of sperm DNA contaminating the sample.

Embryos are cultured, biopsied at the appropriate stage, and frozen. The biopsy samples are sent for analysis. Once results are available, the fertility specialist and genetics team discuss which embryos may be considered for transfer based on the result, embryo development, and the patient’s overall situation. A later Embryo Transfer: Timing, Preparation, and Success Factors" class="ahp-ilk">frozen embryo transfer is then planned if an embryo is available and the patient chooses to proceed.

For patients traveling for care, Acıbadem Health Point’s multidisciplinary fertility and genetics specialists in JCI-accredited hospitals can coordinate assessment and treatment planning for international patients.

Benefits, Limits, and Possible Risks

The main potential benefit of PGT is more genetic information before embryo transfer. For families with a known inherited condition or chromosome rearrangement, it may reduce the chance of transferring an embryo with the specific genetic finding being tested. In selected IVF situations, PGT-A may help guide embryo prioritization, but it cannot ensure implantation or prevent every miscarriage.

PGT has important limits. A biopsy examines only the sampled cells, and embryos can contain a mixture of cells with different chromosome patterns, known as mosaicism. Test results may therefore be inconclusive or may not fully represent the embryo. Some embryos may not survive to biopsy, may not produce a result, or may not be considered suitable for transfer.

Embryo biopsy is performed by experienced embryology teams and is generally considered low risk when done with established techniques. However, IVF itself has possible physical and emotional burdens. Ovarian stimulation can cause bloating, discomfort, mood changes, and, rarely, ovarian hyperstimulation syndrome. Egg collection has uncommon procedural risks such as bleeding, infection, or anesthesia-related complications.

PGT does not replace recommended prenatal screening or diagnostic testing during pregnancy. Depending on the test indication and result, a clinician may discuss options such as chorionic villus sampling or amniocentesis to confirm fetal genetic information.

Recovery Timeline and Self-Care During IVF With PGT

After egg collection, mild pelvic cramping, spotting, tiredness, and bloating can occur for a few days. Most people can return to usual light activities within one or two days, although the clinical team may advise avoiding strenuous exercise, heavy lifting, and sexual intercourse for a short period. Recovery varies with the number of follicles, individual response to medication, and any underlying health conditions.

There is no physical recovery period from embryo biopsy for the patient because the procedure is performed in the laboratory. However, waiting for genetic results and deciding what to do with them can be emotionally demanding. Counseling, clear communication with the fertility team, and support from a trusted partner, family member, or mental health professional can be helpful.

Before embryo transfer, the uterine lining may be prepared with natural-cycle monitoring or prescribed hormones. After transfer, patients should follow their clinic’s individualized instructions and continue medications only as directed. Normal gentle activity is usually acceptable, but patients should contact their care team if they are uncertain about symptoms or medications.

Healthy habits such as avoiding smoking, limiting alcohol, eating a balanced diet, taking prescribed prenatal supplements, and managing chronic conditions can support general reproductive health. These measures cannot change an embryo’s genetic result, but they may support preparation for pregnancy.

When to Seek Medical Care

Anyone considering IVF with PGT should arrange a consultation with a reproductive medicine specialist and, when a genetic condition is involved, a genetic counselor. Medical advice is especially important before beginning treatment if there is a known genetic diagnosis, a chromosome test result, recurrent pregnancy loss, a previous affected pregnancy, or a family history of an inherited disorder.

After ovarian stimulation or egg retrieval, prompt medical advice is needed for severe or worsening abdominal pain, rapidly increasing bloating, shortness of breath, persistent vomiting, fainting, fever, heavy bleeding, or reduced urination. These symptoms are uncommon but may need assessment, particularly because they can signal complications such as ovarian hyperstimulation syndrome or infection.

Emotional distress also deserves care. If fertility treatment or genetic decision-making is causing persistent anxiety, low mood, sleep problems, relationship strain, or difficulty managing daily life, patients should speak with their fertility team or a qualified mental health professional. Support is a routine and valuable part of fertility care.

Frequently asked questions